Equities research analysts expect that Voyager Therapeutics, Inc. (NASDAQ:VYGR) will post earnings per share of ($0.76) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Voyager Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.92). Voyager Therapeutics posted earnings of ($0.57) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The business is expected to issue its next quarterly earnings report on Wednesday, March 21st.

According to Zacks, analysts expect that Voyager Therapeutics will report full-year earnings of ($3.01) per share for the current financial year, with EPS estimates ranging from ($3.20) to ($2.74). For the next financial year, analysts expect that the company will report earnings of ($3.17) per share, with EPS estimates ranging from ($4.16) to ($1.98). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Voyager Therapeutics.

VYGR has been the subject of a number of research reports. Chardan Capital restated a “hold” rating and set a $17.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Canaccord Genuity initiated coverage on shares of Voyager Therapeutics in a research report on Friday, October 27th. They set a “buy” rating and a $35.00 target price for the company. ValuEngine upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Stifel Nicolaus started coverage on shares of Voyager Therapeutics in a research report on Friday, July 28th. They set a “buy” rating and a $20.00 target price for the company. Finally, Raymond James Financial, Inc. started coverage on shares of Voyager Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $35.00 price objective for the company. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company’s stock. Voyager Therapeutics presently has an average rating of “Buy” and a consensus target price of $28.89.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Voyager Therapeutics, Inc. (VYGR) to Announce -$0.76 EPS” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/11/12/zacks-analysts-anticipate-voyager-therapeutics-inc-vygr-to-announce-0-76-eps.html.

In other Voyager Therapeutics news, insider Bernard Ravina sold 16,470 shares of the stock in a transaction on Monday, September 11th. The shares were sold at an average price of $12.87, for a total transaction of $211,968.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 32,940 shares of company stock valued at $490,092 in the last quarter. 8.00% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in shares of Voyager Therapeutics by 20.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock worth $477,000 after acquiring an additional 9,207 shares during the last quarter. Hershey Trust Co. lifted its holdings in shares of Voyager Therapeutics by 163.0% in the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after acquiring an additional 8,921 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Voyager Therapeutics by 9.3% in the 2nd quarter. Wells Fargo & Company MN now owns 91,384 shares of the company’s stock worth $819,000 after acquiring an additional 7,807 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Voyager Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after acquiring an additional 19,450 shares during the last quarter. Finally, Bessemer Group Inc. lifted its holdings in shares of Voyager Therapeutics by 148.1% in the 2nd quarter. Bessemer Group Inc. now owns 44,828 shares of the company’s stock worth $402,000 after acquiring an additional 26,763 shares during the last quarter. Institutional investors and hedge funds own 40.94% of the company’s stock.

Shares of Voyager Therapeutics (NASDAQ:VYGR) traded up $0.17 during trading hours on Friday, hitting $13.60. 1,005,100 shares of the company were exchanged, compared to its average volume of 791,007. Voyager Therapeutics has a 12-month low of $8.10 and a 12-month high of $25.99.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.